Skip to content

{ Tag Archives } Topical Drug

BioCis Pharma Reports Positive Phase IIa Clinical Results In Atopic Dermatitis

BioCis Pharma Ltd., a privately held drug development company with its headquarters in Turku, Finland, announced positive results from its Phase IIa clinical trial of ProtoCure(TM) emulsion cream, the company’s novel topical drug for dermatology. This double-blind, placebo-controlled study, conducted in Finland, included 13 patients with mild to moderate atopic dermatitis who applied the ProtoCure [...]

Bookmark and Share Also tagged , , , , , , , , ,
2009 07 04 Skin Care News Comments Off

Provectus Pharmaceuticals Completes Patient Accrual In Initial Phase 2 Study Of PH-10 For Atopic Dermatitis

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis. PH-10 is the Company’s topical drug for the treatment of dermatologic diseases, including atopic dermatitis, a chronic skin condition that includes some forms of eczema.

Bookmark and Share Also tagged , , , , , , , , , , , , ,
2009 07 02 Skin Care News Comments Off

BioCis Pharma Starts Phase IIa Trial In Psoriasis

BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun a new Phase IIa clinical testing of ProtoCure(TM) emulsion cream, the company’s novel topical drug for dermatology. The double-blind, vehicle-controlled study is designed to evaluate the tolerability, pharmacokinetics, and efficacy of the topical product in a [...]

Bookmark and Share Also tagged , , , , , , , ,
2009 03 13 Skin Care News Comments Off